| Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment VC Yan, FL Muller ACS Medicinal Chemistry Letters 11 (7), 1361–1366, 2020 | 161 | 2020 |
| NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis MK Park, L Zhang, KW Min, JH Cho, CC Yeh, H Moon, ... Cell metabolism 33 (12), 2380-2397. e9, 2021 | 91 | 2021 |
| An enolase inhibitor for the targeted treatment of ENO1-deleted cancers YH Lin, N Satani, N Hammoudi, VC Yan, Y Barekatain, S Khadka, ... Nature Metabolism 2, 1413–1426, 2020 | 48 | 2020 |
| Why Great Mitotic Inhibitors Make Poor Cancer Drugs VC Yan, HE Butterfield, AH Poral, MJ Yan, KL Yang, CD Pham, FL Muller Trends in Cancer 6 (11), 924-941, 2020 | 47 | 2020 |
| Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola VC Yan, FL Muller Antimicrobial Agents and Chemotherapy 65 (10), e01117-21, 2021 | 31 | 2021 |
| Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine Y Barekatain, JJ Ackroyd, VC Yan, S Khadka, L Wang, KC Chen, ... Nature communications 12 (1), 4228, 2021 | 26 | 2021 |
| Caspase-3 substrates for noninvasive pharmacodynamic imaging of apoptosis by PET/CT BJ Engel, ST Gammon, R Chaudhari, Z Lu, F Pisaneschi, H Yang, ... Bioconjugate Chemistry 29 (9), 3180-3195, 2018 | 20 | 2018 |
| An optimized bioassay for screening combined anticoronaviral compounds for efficacy against feline infectious peritonitis virus with pharmacokinetic analyses of GS-441524 … S Cook, L Wittenburg, VC Yan, JH Theil, D Castillo, KL Reagan, ... Viruses 14 (11), 2429, 2022 | 16 | 2022 |
| Eradication of ENO1-deleted glioblastoma through collateral lethality YH Lin, N Satani, N Hammoudi, JJ Ackroyd, S Khadka, VC Yan, ... bioRxiv, 331538, 2018 | 16 | 2018 |
| Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir’s Nephrotoxicity VC Yan, FL Muller Antimicrobial Agents and Chemotherapy 64 (12), e01920-20, 2020 | 15 | 2020 |
| The 3S Enantiomer Drives Enolase Inhibitory Activity in SF2312 and Its Analogues F Pisaneschi, YH Lin, PG Leonard, N Satani, VC Yan, N Hammoudi, ... Molecules 24 (13), 2510, 2019 | 13 | 2019 |
| Targeting host glycolysis as a strategy for antimalarial development AJ Jezewski, YH Lin, JA Reisz, R Culp-Hill, Y Barekatain, VC Yan, ... Frontiers in Cellular and Infection Microbiology 11, 730413, 2021 | 11 | 2021 |
| Pharmacokinetics of Orally Administered GS-441524 in Dogs VC Yan, S Khadka, K Arthur, CD Pham, MJ Yan, AJ Yan, JJ Ackroyd, ... bioRxiv, 2021 | 10 | 2021 |
| Antimicrobial prodrug activation by the staphylococcal glyoxalase GloB MO Mikati, JJ Miller, DM Osbourn, Y Barekatain, N Ghebremichael, ... ACS infectious diseases 6 (11), 3064-3075, 2020 | 9 | 2020 |
| Comprehensive summary supporting clinical investigation of GS-441524 for Covid-19 treatment V Yan, F Muller OSF Preprints, 2020 | 8 | 2020 |
| Remdesivir for COVID-19: Why Not Dose Higher? VC Yan, FL Muller Antimicrobial Agents and Chemotherapy 65, e2713-20, 2021 | 7 | 2021 |
| Aliphatic amines are viable pro-drug moieties in phosphonoamidate drugs VC Yan, CD Pham, K Arthur, KL Yang, FL Muller Bioorganic & Medicinal Chemistry Letters 30 (24), 127656, 2020 | 6 | 2020 |
| First-in-Woman safety, tolerability, and pharmacokinetics of orally administered GS-441524: A broad-spectrum antiviral treatment for COVID-19 V Yan OSF, 2021 | 5 | 2021 |
| Gilead should ditch remdesivir and focus on its simpler and safer ancestor VC Yan, FL Muller Boston Globe Media Partners, 2020 | 5 | 2020 |
| Expedient method for direct mono-amidation of phosphonic and phosphoric acids VC Yan, CD Pham, FL Muller chemRxiv, 2020 | 4 | 2020 |
Florian MullerAssistant Professor UT MD Anderson Cancer CenterVerified email at mdanderson.org
